Disease · MONDO_0007186
Comparisons in its trials89
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 89
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Placebo BID + PPIs vs 1500 mg IW-3718 BID + PPIs: deaths from any cause | 1 of 304 | 0 of 304 | 608 | NCT03561883 | Trial comparisons |
| Placebo BID + PPIs vs 1500 mg IW-3718 BID + PPIs: serious adverse events | 3 of 304 | 2 of 304 | 608 | NCT03561883 | Trial comparisons |
| Esomeprazole Surgical Arm vs Esomeprazole Medical Arm: Los Angeles (LA) Grade 'B' at 5 Year Visit | 5 of 288 | 7 of 266 | 554 | NCT00251927 | Trial comparisons |
| Esomeprazole Surgical Arm vs Esomeprazole Medical Arm: Investigator-assessed Heartburn Severity at 5 Year Visit, Participants With no Heartburn | 163 of 288 | 161 of 266 | 554 | NCT00251927 | Trial comparisons |
| Esomeprazole Surgical Arm vs Esomeprazole Medical Arm: Los Angeles (LA) Grade 'Normal' at 5 Year Visit | 144 of 288 | 158 of 266 | 554 | NCT00251927 | Trial comparisons |
| Esomeprazole Surgical Arm vs Esomeprazole Medical Arm: Investigator-assessed Heartburn Severity at 5 Year Visit, Participants With Severe Heartburn | 0 of 288 | 2 of 266 | 554 | NCT00251927 | Trial comparisons |
| Esomeprazole Surgical Arm vs Esomeprazole Medical Arm: Investigator-assessed Heartburn Severity at 5 Year Visit, Participants With Moderate Heartburn | 3 of 288 | 3 of 266 | 554 | NCT00251927 | Trial comparisons |
| Esomeprazole Surgical Arm vs Esomeprazole Medical Arm: Number of Participants With Treatment Failure at 5 Years | 33 of 288 | 19 of 266 | 554 | NCT00251927 | Trial comparisons |
| Esomeprazole Surgical Arm vs Esomeprazole Medical Arm: Los Angeles (LA) Grade 'A' at 5 Year Visit | 12 of 288 | 16 of 266 | 554 | NCT00251927 | Trial comparisons |
| Esomeprazole Surgical Arm vs Esomeprazole Medical Arm: Investigator-assessed Heartburn Severity at 5 Year Visit, Participants With Mild Heartburn | 11 of 288 | 25 of 266 | 554 | NCT00251927 | Trial comparisons |
| Esomeprazole Surgical Arm vs Esomeprazole Medical Arm: Los Angeles (LA) Grade C at 5 Year Visit | 1 of 288 | 2 of 266 | 554 | NCT00251927 | Trial comparisons |
| Placebo BID + PPI vs 1500 mg IW-3718 BID + PPI: deaths from any cause | 0 of 246 | 0 of 247 | 493 | NCT03561090 | Trial comparisons |
| Placebo BID + PPI vs 1500 mg IW-3718 BID + PPI: serious adverse events | 0 of 246 | 3 of 247 | 493 | NCT03561090 | Trial comparisons |
| TAK-438 10 mg vs Placebo: deaths from any cause | 0 of 238 | 0 of 245 | 483 | NCT02954848 | Trial comparisons |
| TAK-438 10 mg vs Placebo: serious adverse events | 0 of 238 | 1 of 245 | 483 | NCT02954848 | Trial comparisons |
| Vonoprazan 20 mg vs Lansoprazole 30 mg: Number of Participants Reporting Who Had One or More Treatment-emergent Adverse Event (TEAE) | 93 of 244 | 86 of 235 | 479 | NCT02388724 | Trial comparisons |
| Vonoprazan 20 mg vs Lansoprazole 30 mg: deaths from any cause | 0 of 244 | 0 of 235 | 479 | NCT02388724 | Trial comparisons |
| Vonoprazan 20 mg vs Lansoprazole 30 mg: serious adverse events | 3 of 244 | 3 of 235 | 479 | NCT02388724 | Trial comparisons |
| 4 Week Group vs 8 Week Group: The Rates of Complete Symptom Relief | 152 of 207 | 157 of 201 | 408 | NCT01874535 | Trial comparisons |
| 4 Week Group vs 8 Week Group: deaths from any cause | 0 of 207 | 0 of 201 | 408 | NCT01874535 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007186/comparisons